The clinical utilization of humanized monoclonal ICIs of PD-1 (pembrolizumab and nivolumab) and PD-L1 (atezolizumab, avelumab, and durvalumab) is widely established as effective cancer therapy [31,32]. The gene discussed is PDCD1; the disease is cancer.